A Single Centre, Double-Blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura

Trial Profile

A Single Centre, Double-Blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Tonabersat (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Minster Pharmaceuticals
  • Most Recent Events

    • 10 Sep 2009 Results have been reported at the 14th International Headache Congress & the 51st Annual Scientific Meeting of the American Headache Society (Joint meeting; AHS/IHS 2009).
    • 01 Sep 2009 Actual number of patients changed from 31 to 39 as reported by ClinicalTrials.gov.
    • 24 Oct 2008 Status changed from recruiting to completed as reported in a Minster Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top